Table 1.
Characteristics | N (%) N = 21 |
---|---|
Median Age (range) | 66 years (47–78) |
Gender | |
Female | 4 (19.0) |
Male | 17 (81.0) |
ECOG* performance status | |
0 | 4 (19.0) |
1 | 17 (81.0) |
Diagnosis | |
castration-resistant prostate cancer | 11 (52.4) |
Pancreatic cancer | 7 (33.3) |
Melanoma | 2 (9.5) |
HPV- head and neck squamous cell carcinoma | 1 (4.8) |
Median number of prior systemic therapies (range) | 4 (1–9) |
Prior immune checkpoint inhibitor | 4 (19.0) |
HPV- head and neck squamous cell carcinoma | 1 (4.8) |
Melanoma | 2 (9.5) |
Castration-resistant prostate cancer | 1 (4.8) |
Median number of evofosfamide doses (range) | 4 (2–8) |
Median number of ipilimumab doses (range) | 4 (1–8) |
ECOG Eastern Cooperative Oncology Group